Albumin-interferon-α (alb-IFN) is a novel recombinant protein derived from IFN-α2b genetically fused to human albumin. The resulting single polypeptide combines in one molecule the antiviral properties of IFN-α with the long serum half-life of albumin. IFN-mediated biological responses stem from the engagement of IFN-α with its target receptor and subsequent modulation of IFN-specific gene (ISG) expression. To evaluate the pharmacodynamics of alb-IFN during the Phase I/II study conducted in patients with chronic hepatitis C (CHC) who had previously failed IFN-α-containing regimens, ISG induction was evaluated in peripheral blood and compared with antiviral response. Whole blood was obtained at day 0, day 7 and day 28 from 21 patients enrolled in the higher dose (500–900 μg) alb-IFN cohort, who received two injections on day 0 and day 14. Taqman real-time PCR was used to assess candidate ISG expression. There was sustained induction on day 7 and day 28 of the ISG's OAS1, IRF-7, IFI44 and IFI27. Although all patients showed a molecular response to alb-IFN, individual variability in pretreatment gene expression levels and fold of modulation during treatment was observed. At day 28, induction of OAS1, IFI44 and IRF7 showed pairwise correlation in individual patients (P<0.05). Moreover, the induction of expression at day 28, and pretreatment levels of OAS1 and IFI44 correlated with hepatitis C virus RNA reduction at day 28 (P<0.05). In conclusion, alb-IFN demonstrated robust induction of ISG that was consistent with the response associated with an IFN-α.
References
1.
TilgH.New insights into the mechanisms of interferon: an immunoregulatory and anti-inflammatory cytokine.Gastroenterology1997; 112: 1017–1021.
2.
FeldJ.J., HoofnagleJ.H.Mechanism of action of interferon and ribavirin in treatment of hepatitis C.Nature2005; 436: 967–972.
3.
OsbornB.L., OlsenH.S., NardelliB.Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys.J Pharmacol Exp Ther2002; 303: 540–548.
4.
BalanV., SulkowskiM., NelsonD.A Phase I/II study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of recombinant human albumin-Interferon alpha fusion protein in patients with chronic hepatitis C who have failed previous interferon alpha-based therapy.Antivir Ther2006; 11: 35–45.
5.
BalanV., SulkowskiM., NelsonD.Molecular profiles of drug response in HCV infected patients during the first 4 weeks of therapy for chronic hepatitis C virus with pegylated interferon containing regimens or Albuferon.Hepatology2003; 38 Suppl 1: 630A, Abstract 984.
6.
DerS.D., ZhouA., WilliamsB.R.G., SilvermanR.H.Identification of genes differentially regulated by interferon or using oligonucleotide arrays.Proc Natl Acad Sci USA1998; 95: 15623–15628.
7.
de VeerM.J., HolkoM., FrevelM.Functional classification of interferon-stimulated genes identified using microarrays.J Leukoc Biol2001; 69: 912–920.
8.
HayashiJ., StoyanovaR., SeegerC.The transcriptome of HCV replicon expressing cell lines in the presence of alpha interferon.Virology2005; 335: 264–275.
9.
ChenL., BorozanI., FeldJ.Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.Gastroenterology2005; 128: 1437–1444.
10.
HondaK., YanaiH., NegishiH.IRF-7 is the master regulator of type-I interferon-dependent immune responses.Nature2005; 435: 772–777.
11.
KitamuraA., TakahashiK., OkajimaA., KitamuraN.Induction of the human gene for p44, a hepatitis-C-associated microtubular aggregate protein, by interferon-alpha/beta.Eur J Biochem1994; 224: 877–883.
12.
HuangM., QianF., HuY., AngC., LiZ., WenZ.Chromatin-remodelling factor BRG1 selectively activates a subset of interferon-alpha-inducible genes.Nat Cell Biol2002; 4: 774–781.
13.
BareP., MassudI., ParodiC., BelmonteL.Continuous release of hepatitis C virus (HCV) by peripheral blood mononuclear cells and B-lymphoblastoid cell-line cultures derived from HCV-infected patients.J Gen Virol2005; 86: 1717–1727.
